Medically reviewed by Dr. Giovanni Scornavacca — Hair Restoration Specialist, Carisma Hair Clinic, St Julian's, Malta. 20+ years clinical experience, trained in Rome and Bologna.

Medically reviewed by Dr. Giovanni Scornavacca — Hair Restoration Specialist, Carisma Hair Clinic, St Julian's, Malta. 20+ years clinical experience, with advanced training in Rome and Bologna.

Crown Thinning Treatment in Malta: Options and Outcomes

Crown thinning — also called vertex hair loss — responds well to medical treatment in the majority of men who intervene before follicle miniaturisation becomes advanced. Clinical studies indicate that the crown zone is where finasteride, minoxidil, and regenerative protocols produce their most measurable results. Timely assessment and a structured protocol give men in Malta the best prospect of sustained density improvement. Results may vary for each individual depending on the stage of loss and follicle viability at the time of treatment.

There is a particular moment that many men in our consultation room describe with unexpected precision. Not a morning in front of the bathroom mirror — the bathroom mirror rarely shows the crown. It is the hotel room, the shop window at an oblique angle, or more often now, the accidental overhead selfie taken by someone else. The phone screen is handed back, and there it is. A patch of scalp visible through thinning hair, at the very top of the head, that they had no idea was there.

Crown thinning has a geography that works against self-detection. The vertex — the topmost region of the scalp — is precisely the zone that a standard frontal mirror examination conceals. Men who have been monitoring their hairline carefully for years can be unaware of significant crown thinning that colleagues, family members, and barbers have been quietly noting for much longer.

This article explains why the crown is often the most androgen-sensitive area on the scalp, how to assess it honestly, and what crown thinning treatment Malta options are available for men who have identified a problem and are ready to act.

Contents

• ›Why Crown Thinning Progresses Differently from Hairline Recession
• ›The Visibility Problem: Why Others Know Before You Do
• ›What a Clinical Assessment Shows at the Vertex
• ›Treatment Options for Crown Thinning in Malta
• ›Why the Crown Responds Well to Treatment
• ›What a Realistic Treatment Timeline Looks Like
• ›Frequently Asked Questions About Crown Thinning Treatment in Malta

Why Crown Thinning Progresses Differently from Hairline Recession

Understanding crown thinning as a distinct clinical presentation matters before considering treatment. In many men with androgenetic alopecia, the crown and the hairline do not progress together. The vertex is an independent zone of androgen sensitivity, and for a significant proportion of men — particularly those presenting as Norwood Stage III Vertex or Norwood IV — the crown begins thinning while the frontal hairline remains substantially intact.

The mechanism is the same as hairline loss: dihydrotestosterone (DHT) binds to androgen receptors in genetically susceptible follicles at the crown. This initiates a cycle of follicular miniaturisation, progressively shortening the growth phase and thinning each hair shaft. Over repeated cycles, terminal hairs are replaced by finer vellus hairs and, eventually, the follicle ceases to produce visible hair. The distinction is that the androgen receptor density and DHT sensitivity at the vertex can be higher than at other scalp zones, meaning loss here sometimes precedes or outpaces recession at the temples.

Evidence suggests that this vertex-dominant pattern is a recognised clinical subtype of androgenetic alopecia, not an anomaly. According to the PMC review on androgenetic alopecia, the vertex follicle population carries a genetically determined susceptibility to DHT-mediated miniaturisation that can differ significantly from frontal follicles in the same individual.

This has direct clinical relevance: if your hairline has held relatively stable while you have noticed progressive crown coverage loss, this is a recognised pattern. It also means that treatment targeting the DHT mechanism can be highly effective at the crown, because the follicles there are often still viable and responsive, even when loss appears significant. Understanding male pattern baldness Malta in its full presentation is the first step toward making sense of what you are observing at the vertex.

The Visibility Problem: Why Others Know Before You Do

The crown is the only major hair loss zone where the patient is structurally the last person to see it. The scalp's topographic position means that ordinary mirrors, at standing height and standard angles, consistently obscure the vertex. A man can have Norwood Stage IV vertex involvement — measurable thinning across the central crown — and remain genuinely unaware of its extent for years.

The mechanisms of delayed self-detection are worth naming, because they affect when men present for treatment — and therefore what can be achieved:

Gradual onset. Androgenetic alopecia at the crown progresses slowly. Individual hairs miniaturise over months. The aggregated change across a scalp zone accumulates across years. No single day announces itself as "the day the crown began thinning."

Styling adaptation. Men unconsciously adapt their hair direction, volume application, and parting to compensate for increasing transparency at the crown. This adaptation is effective — until it is not.

Mirror geometry. Without a hand mirror held above and behind the head, a man cannot accurately see his own crown. Most men do not routinely do this.

The honest self-test. The most direct tool available is a smartphone camera. Hold the phone at arm's length above your head, angled downward at 45 degrees, and take a photograph. Then hold it level with the crown and photograph straight down. These two images, taken in natural light without styling product, show the scalp in the same way a barber or an overhead CCTV camera does. They are more accurate than any mirror-based assessment.

If those photographs show visible scalp through the hair, or a zone where the hair appears notably thinner and sparser than the surrounding density, this warrants clinical assessment — not because the result is alarming, but because earlier intervention produces more options and better outcomes.

What a Clinical Assessment Shows at the Vertex

A self-photograph is useful for recognising that something has changed. It is not a substitute for clinical assessment, which provides the information needed to determine whether treatment is appropriate and, if so, which protocol is most likely to produce results.

At Carisma Hair Clinic, every patient presenting with crown thinning undergoes a structured evaluation that includes scalp imaging and density mapping at the vertex. This examination serves several functions that the overhead phone test cannot:

Quantifying follicle density. Trichoscopy (scalp microscopy) allows direct visualisation and counting of follicular units in the affected zone. A clinician can differentiate between terminal hairs, miniaturised vellus hairs, and empty follicular units. This determines how much viable follicle tissue remains.

Identifying miniaturisation patterns. Early-stage miniaturisation — where follicles are thinning but have not yet entered dormancy — responds substantially better to medical treatment than advanced miniaturisation with high vellus-to-terminal ratios. Knowing which stage the follicles are at changes the treatment recommendation.

Establishing baseline for monitoring. Density imaging at the initial visit creates a quantified baseline against which response to treatment can be measured at 90 and 180 days. This removes the subjectivity from "is this working?" and replaces it with measurable data.

Norwood staging. The Norwood scale Malta classification provides a standardised description of the pattern and extent of loss, which guides both treatment choice and realistic expectation-setting. Crown-dominant presentations are classified as III Vertex through VII.

The combination of clinical history, scalp imaging, and Norwood staging gives a complete picture in a single consultation. It is the basis on which every treatment decision is made.

Treatment Options for Crown Thinning in Malta

The crown's high androgen sensitivity, which makes it vulnerable to DHT-driven miniaturisation, also makes it one of the most responsive zones to treatments that work through the DHT mechanism. Clinical trial data specifically include subgroup analyses of the vertex, because it was recognised early in the development of both finasteride and minoxidil that the crown and the hairline respond differently — and that the crown typically responds better.

Finasteride: Systemic DHT Reduction

Finasteride 1 mg, taken daily, inhibits the type II 5-alpha reductase enzyme responsible for converting testosterone to DHT. In pivotal clinical trials, serum DHT may be reduced by approximately 71% and scalp DHT by approximately 64%. The original finasteride RCT published on PubMed established these figures and remains the foundational reference for the medication's efficacy profile.

Critically, the efficacy data from these trials were stratified by scalp zone. At the vertex, 83% of men treated with finasteride showed no further hair loss over two years, compared with continued loss in the placebo group. Visible regrowth at the vertex was observed in approximately 61–66% of men at the two-year mark. These figures are substantially more favourable than the data for the frontal zone (approximately 37%), which reflects the greater androgen responsiveness of the crown.

For men with crown-dominant hair loss who have not yet begun medical treatment, finasteride may be the first-line systemic option. Its mechanism directly targets the hormonal driver of vertex miniaturisation. Treatment is continuous — effects are maintained only while the medication is taken, and hair loss can resume within months of stopping.

Finasteride is a prescription-only medicine in Malta and across the EU. It is available only following consultation with a licensed healthcare professional. A small percentage of men — approximately 2–5% in clinical trials — report sexual side effects, which typically resolve after stopping the medication. Results may vary for each individual.

For information on accessing finasteride in Malta, see our dedicated guide on finasteride Malta.

Minoxidil 5%: Topical Stimulation at the Vertex

Topical minoxidil works through a different mechanism from finasteride — it acts as a potassium channel opener at the follicular level, promoting vasodilation, increasing blood flow to the dermal papilla, and prolonging the anagen (growth) phase. It does not affect DHT levels.

Clinical studies indicate that 60–70% or more of men using topical minoxidil may experience measurable improvement in hair density. A pivotal 48-week randomised controlled trial of 393 men found that the 5% formulation produced approximately 45% more non-vellus hair regrowth than the 2% formulation (18.6 versus 12.7 hairs added in the target area), establishing 5% as the standard recommended concentration for men. The PMC review of minoxidil evidence provides a comprehensive summary of the clinical evidence supporting topical use.

For vertex application specifically, technique matters. The minoxidil solution or foam should be applied directly to the crown — parting the hair to access the scalp rather than applying to the hair shaft — and massaged in to ensure contact with the follicular surface. The vertex can be harder to reach than the temples, which means some men inadvertently apply product to hair rather than scalp. Correct application technique is worth confirming at a clinical appointment.

Minoxidil must be used continuously to maintain results. Within six to twelve months of stopping, any density gains are typically reversed.

Evidence suggests that combining finasteride and minoxidil can produce better results than either treatment alone. Multiple meta-analyses confirm that combination therapy produces significantly greater improvements in hair density and diameter than monotherapy at the vertex.

For a detailed comparison of these two medications, see finasteride vs minoxidil Malta. For a deep-dive into the 5% strength specifically and who qualifies, see our guide on minoxidil 5% for vertex loss.

PRP and Exosome Protocol: Targeted Regenerative Treatment

For men seeking to go beyond medication alone — or those who prefer not to take daily oral medication — the PRP (platelet-rich plasma) and exosome protocol offers a clinically supported regenerative option directly administered to the crown follicle zones.

PRP is prepared from the patient's own blood. A sample is processed in a centrifuge to concentrate the platelets, which contain growth factors including PDGF, VEGF, and IGF-1 — proteins that promote angiogenesis and stimulate follicle keratinocytes. The concentrated plasma is then injected into the scalp at the vertex using a micro-injection technique, delivering growth factors directly to the follicular environment.

Clinical literature reports density improvements of 25–40% in hair density metrics over six months with PRP protocols. A systematic review of PRP for androgenetic alopecia published on PubMed found that PRP injections produced statistically significant improvements in hair density and thickness compared to controls, though the authors noted variability in preparation methods across studies. The evidence base is more heterogeneous than for finasteride or minoxidil — study designs, PRP preparation methods, and outcome measures vary. The mechanistic rationale and clinical results position PRP as a meaningful adjunct, particularly at the vertex where viable follicles remain.

The addition of exosomes — extracellular vesicles containing signalling proteins and growth factors derived from stem cell cultures — is a more recent component of regenerative hair protocols. Exosomes are believed to amplify the signalling environment created by PRP, supporting follicle transition from telogen to anagen more effectively than PRP alone. The evidence base for exosomes is still developing, but early clinical data are consistent with the proposed mechanism.

The Hair Reset Protocol at Carisma Hair Clinic incorporates PRP and exosome injections targeted to the vertex follicle zones as part of a structured 90-day programme under the supervision of Dr. Giovanni Scornavacca. The crown is where the protocol has produced its most consistent and measurable results, because — unlike advanced frontal recession — the vertex typically retains a higher proportion of follicles that are miniaturised but not yet dormant.

For a full overview of PRP hair treatment Malta and the regenerative component of the Hair Reset Protocol, the treatments page details the complete protocol.

PRP and exosome injections are applied directly to the vertex follicle zones during the Hair Reset Protocol. Photo: cottonbro studio / Pexels

Why the Crown Responds Well to Treatment

A question that patients with significant crown thinning frequently ask is whether the process has progressed too far to benefit from non-surgical treatment. The answer, in most cases, is that the crown responds better than expected — and this reflects documented clinical biology, not reassurance designed to secure consultations.

The reason is follicle viability. Advanced frontal recession — particularly at the temples and the leading edge of a receding hairline — tends to involve a higher proportion of terminally miniaturised or dormant follicles. These follicles have completed multiple shortened anagen cycles and are no longer producing visible hair. Treatments that stimulate follicle activity cannot revive follicles that have irreversibly ceased function.

At the crown, particularly in Norwood Stage III Vertex through Stage V presentations with crown-dominant loss, the follicles are often at an earlier stage of miniaturisation. Scalp imaging reveals miniaturised terminal hairs and vellus hairs that are still present in the follicular units — they are producing finer, shorter, less pigmented hair, but they are biologically active. This is the window in which treatment is most likely to produce a measurable reversal of miniaturisation.

The implication is directionally encouraging: even if the scalp is visibly showing thinning at the crown, there is meaningful probability that the follicles responsible are still responsive to the right treatment protocol. The receding hairline treatment Malta guide explores the contrast between frontal and vertex response in more detail.

What a Realistic Treatment Timeline Looks Like

Clinical honesty about timelines is important. The treatments described above take time, and the trajectory is not linear.

Months 1–3 (the silent phase): Finasteride and minoxidil are both working at the follicular level, but visible change is not expected in most patients during this period. Some patients on minoxidil experience increased shedding in weeks two through eight — a well-recognised effect as the medication shifts resting follicles into the growth phase, temporarily displacing existing hairs. This is not a sign of treatment failure.

Months 3–6 (early response): The 90-day scalp imaging assessment at Carisma Hair Clinic uses density mapping to detect changes in follicle counts and hair calibre at the vertex that are not yet visible to the naked eye. The Hair Reset Protocol has documented an average 21–28% density increase at 90 days, measured by scalp imaging. For many patients, this is the first objective confirmation that the protocol is working.

Months 6–12 (consolidation and visible change): Visible density improvement at the crown becomes apparent during this phase in patients who are responding to treatment. Hair shaft calibre increases, vellus hairs transition to terminal hairs, and the scalp is less visible through the hair.

Month 12 onwards (maintenance assessment): The full 12-month outcome is the reference point for evaluating treatment success. Some patients achieve continued improvement beyond 12 months on continuous treatment. The maintenance requirement is non-negotiable — stopping treatment reverses gains.

Ready to Take Control of Your Hair Loss?

If you have been researching your options and want a clinical assessment rather than another generic recommendation, Carisma Hair Clinic offers a comprehensive diagnostic consultation — scalp imaging, density mapping, and a personalised protocol designed around your specific pattern of loss.

→ Book Your Free Hair Loss Consultation

Dr. Giovanni Scornavacca and the team at Carisma Hair Clinic are available at our St Julian's clinic.

Frequently Asked Questions About Crown Thinning Treatment in Malta

What causes thinning at the crown of the head?

Crown thinning in men is most commonly caused by androgenetic alopecia — genetic hair loss driven by DHT (dihydrotestosterone) binding to androgen receptors in scalp follicles. The vertex is frequently a zone of high androgen receptor sensitivity, meaning DHT-driven miniaturisation can begin and progress there independently of hairline recession. Other causes — including thyroid dysfunction, iron deficiency, and stress-related telogen effluvium — can also affect the crown but typically present with more diffuse loss across the whole scalp. A clinical assessment including blood tests where indicated is the accurate way to confirm the cause before beginning treatment.

Is crown thinning reversible?

In many cases, partial or significant reversal of crown thinning may be achievable with timely medical treatment. The key variable is follicle viability. Where follicles at the vertex are miniaturised but still biologically active — which scalp imaging can determine — treatments including finasteride, minoxidil, and PRP-based protocols can help stimulate recovery of hair density. Completely dormant follicles do not respond to medical treatment. This is why earlier assessment and intervention tend to produce better outcomes: the window of follicle viability is finite. Results may vary for each individual.

Does minoxidil work on crown thinning?

Yes. Clinical trials specifically measuring vertex response to minoxidil show that 60–70% or more of men may experience measurable density improvement. The 5% formulation produces significantly more regrowth than 2% at the vertex. Minoxidil does not affect DHT levels, so it is often used alongside finasteride for a complementary mechanism. Application technique at the crown — ensuring product contacts the scalp rather than the hair — is important for efficacy.

How effective is PRP for crown hair loss?

Clinical literature reports density improvements of approximately 25–40% in hair metrics over six months with PRP protocols targeting the scalp. The vertex responds particularly well because it tends to retain viable follicles even when visually significant thinning has occurred. At Carisma Hair Clinic, PRP and exosome injections are administered as part of the Hair Reset Protocol, with density imaging at 90 days providing an objective measure of response. Results vary between individuals depending on stage of loss and follicle viability at the time of treatment.

How much does crown thinning treatment cost in Malta?

The cost of crown thinning treatment in Malta depends on the specific protocol recommended following your clinical assessment. Medical treatments such as finasteride (prescription required) and topical minoxidil carry an ongoing monthly cost for medication. The Hair Reset Protocol at Carisma Hair Clinic — which incorporates scalp imaging, PRP and exosome injections, and a structured 90-day programme — is priced based on the number of sessions and the extent of the vertex zone being treated. A free initial consultation with scalp imaging is available, after which Dr. Scornavacca will outline a protocol and associated costs specific to your presentation.

How long does it take to see results from crown thinning treatment?

Visible results typically emerge between three and six months of consistent treatment. The 90-day scalp imaging assessment detects measurable changes in follicle density and hair calibre that often precede visible change. A full 12-month period is required for a comprehensive evaluation of treatment outcome. Both finasteride and minoxidil must be taken continuously — hair gains are typically lost within six to twelve months of stopping either medication.

Can crown thinning be treated without surgery?

Yes. The majority of men with crown thinning — particularly those who present before advanced follicle dormancy — are suitable candidates for non-surgical treatment. Medical options including finasteride (prescribed) and minoxidil (topical), combined with regenerative protocols such as PRP and exosome injections, can produce meaningful density improvement at the vertex without surgery. Hair transplant surgery is typically discussed only when medical treatment has been insufficient or when follicle viability at the vertex is confirmed to be very low.

Is PRP hair treatment safe, and what are the risks?

PRP is prepared from the patient's own blood, which significantly reduces the risk of allergic reaction or rejection. The procedure involves micro-injections to the scalp, so mild discomfort, temporary redness, or localised swelling at injection sites can occur — these typically resolve within 24–48 hours. Serious adverse events are rare when the procedure is performed in a clinical setting by a qualified practitioner. As with any medical procedure, a full health history is taken before treatment to confirm suitability. Consult your healthcare professional for a personalised risk assessment.

About the Author

Dr. Giovanni Scornavacca is a hair restoration specialist with over 20 years of clinical experience, with advanced training at universities in Rome and Bologna. He leads the Hair Reset Protocol at Carisma Hair Clinic — Malta's most complete non-surgical hair regrowth programme. Dr. Scornavacca specialises in diagnosing and treating androgenetic alopecia, telogen effluvium, and complex hair loss presentations using PRP, exosome therapy, and tailored prescription protocols.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Results may vary for each individual. Always consult a qualified healthcare professional before starting any hair loss treatment. Finasteride is a prescription-only medication that requires assessment and prescription from a licensed healthcare professional; it must not be used or handled by women who are pregnant or may become pregnant. Minoxidil must be used continuously to maintain results. Dr. Giovanni Scornavacca and Carisma Hair Clinic are available for clinical consultation at our St Julian's, Malta clinic.

Written and reviewed by Dr. Giovanni Scornavacca, Carisma Hair Clinic. Published: 26 June 2026.

Ready to Take Action?

Book a free consultation with Dr. Giovanni Scornavacca to get a personalised hair loss assessment and treatment plan.